Resumo

GONZALEZ, Jairo  e  GONZALEZ, Ana María. COVID-19. Therapeutics options from the viro-pathogenesis to the clinical evidence. Rev. colom. nefrol. [online]. 2020, vol.7, suppl.2, pp.183-193.  Epub 13-Maio-2021. ISSN 2500-5006.  https://doi.org/10.22265/acnef.7.supl.2.433.

We know more and more about this deadly enemy of the Betacoronavirus family, initially called 19- nCoV that causes COVID-19 (Coronavirus infectous disease), today classified SARS-CoV-2, because it is responsible for producing SARS (severe acute respiratory syndrome), It shares a strong sequence homology with SARS-CoV, its cousin that caused the 2003 SARS epidemic, both capable of spreading rapidly, particularly this one and causing great global chaos as has happened with this pandemic. Based on previous studies targeting SARS-CoV, and also on the virus that causes MERS (Middle East Respiratory Syndrome); and with the current knowledge about SARS-CoV-2, we will explore some therapeutic options for the management of infection by this complex and lethal virus, mentioning some aspects of pathogenic relevance.

Possible management alternatives from the pathophysiology and pathogenesis to the evidence currently available were emphasized. We will explore the probable use of ECA2 recombinate, some experimental molecules, we will review some of the antimalarials (chloroquine and hydroxychloroquine), steroids, azithromycin, specific antivirals such as remdesivir, lopinavir / ritonavir, biologics such as tocilizumab, monoclonal antiviral antibodies, and we will emphasize transfusion of convalescent plasma from the passive immunization principle, very useful.

Palavras-chave : SARS-CoV-2; COVID-19; spike protein; chloroquine; remdesivir; convalescent plasma treatment; vaccines.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )